新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » 罗氏$4.9亿收购双特异性抗体平台DutaMab 巩固治疗性抗体领域领先地位

罗氏$4.9亿收购双特异性抗体平台DutaMab 巩固治疗性抗体领域领先地位

来源:生物谷 2014-12-19 10:15

2014年12月19日讯 /生物谷BIOON/ --瑞士制药巨头罗氏(Roche)近日宣布耗资4.89亿美元收购奥地利生物技术公司Dutalys,该公司是一家双特异性抗体发现和开发方面的专家。

目前,双特异性抗体疗法是一种非常火爆的新兴技术,在癌症治疗领域,已被证明比传统抗体更有效。根据协议,罗氏将支付1.3375亿美元的前期付款,在达到特定里程碑后,还将支付额外高达3.55亿美元的里程碑款项,使得该笔交易价达到了4.89亿美元。

通过收购Dutalys,罗氏获得了双特异性抗体平台DutaMab,该平台将为多个治疗领域提供新颖的双特异性抗体药物。罗氏表示,DutaMab平台将补充至自身的双特异性抗体开发系统CrossMab。该笔交易将加强罗氏在治疗性抗体领域的领先地位。在该领域,罗氏已经拥有了一些年销售额数十亿美元的重磅产品,包括安维汀(Avastin)、赫赛汀(Herceptin)、美罗华(Rituxan)、Perjeta、Kadcyla、Gazyva等。除了这些重磅产品,罗氏抗体管线中还有多种实验性抗体药物,开发用于治疗癌症、冠状动脉疾病、多发性硬化症、阿尔茨海默氏症等。

双特异性抗体是一种人造蛋白,由2个不同的单克隆抗体的片段组成,能够结合疾病通路的2个不同的部位。罗氏相信,DutaMab技术开发的全人源化双特异性抗体,具有尤其良好的结合性和稳定性。

Dutalys是一家私人制药公司,成立于2010年4月,该公司得到了来自奥地利Wirtschaftsservice种子资金、奥地利研究促进局和维也纳市科技局研究资金、奥地利学术企业孵化器资金资助。(生物谷Bioon.com)

英文原文:Roche boosts its antibody arsenal with a $489M buyout

Roche ($RHHBY) is betting big on antibodies that can attack two targets at once, signing on to buy Austria's Dutalys for as much as $488.8 million and get its hands on some proprietary technology.

Under the deal, Roche will hand over $133.8 million up front with the promise of up to $355 million more tied to undisclosed development milestones. In exchange, the Swiss drugmaker gets DutaMab, Dutalys' platform for discovering and developing bi-specific antibodies, which can bind to multiple antigens at the same time.

Traditional bi-specific antibodies are crafted by fusing fragments of two antibodies and stitching them together with unnatural linkers, Dutalys said, a process that can lead to problems with stability and manufacturing. DutaMab, in contrast, allows for the development of fully human antibodies in which each arm can bind to both targets, the biotech said. That makes for a more predictable product with applications in diseases previously unaddressable by bi-specific antibodies, according to Dutalys.

And the technology will fit right in at Roche, pRED chief John Reed said. The company has been in the monoclonal antibody game for years, and DutaMab will complement its own bi-specific development system, called CrossMAb.

"The platform developed by Dutalys is a breakthrough technology, and we are excited about integrating it within Roche," Reed said in a statement. "It strengthens our R&D capabilities in delivering bi-specific antibodies, which have the potential to create transformational new medicines."

Roche and its Genentech subsidiary have a storied history of turning promising antibodies into landscape-altering medicines, successfully developing Rituxan, Avastin, Perjeta, Kadcyla, Gazyva and others. Behind those blockbuster therapies is a pipeline with scores of antibody treatments designed to treat cancer, coronary disease, multiple sclerosis and Alzheimer's.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库